Table 8.

Presence or absence of urinary DEHP metabolites as detected from a single urine sample at study enrollment as compared with presence or absence of DEHP exposures during the prior 48 h

Subject (#)a	Respiratory DEHP exposures (days)	IV DEHP exposures (mL)	MEHHP (ng/mL) (mcg/g creatinine)	MEOHP (ng/mL) (mcg/g creatinine)	MEHP (ng/mL) (mcg/g creatinine)
N1d	2 (bubble CPAP)	0	Assay failed	1600 12,000	650 4600
N2b	0	0	< LOD	< LOD	< LOD
N3b	0	0	< LOD	< LOD	< LOD
N4b	0	0	< LOD	< LOD	< LOD
N5d	2 (Hi-flow and ventilator)	9	Assay failed	< LOD No urine creatinine	30 No urine creatinine
N6c	2 (Hi-flow)	0	Assay failed	Assay failed	< LOD
N7e	NA	NA	Not done	Not done	Not done
N8e	NA	NA	Not done	Not done	Not done
N9e	NA	NA	Not done	Not done	Not done
D1d	2 (Ventilator)	10	Assay failed	69 420	32 200
D2e	NA	NA	Not done	Not done	Not done
H1e	NA	NA	Not done	Not done	Not done
H2d	2 (NIPPV)	0	Assay failed	Assay failed	35 240
H3c	2 (NIPPV)	0	< LOD	< LOD	< LOD
H4b	0	0	< LOD	< LOD	< LOD
H5d	2 (Hi-flow)	49	45 400	25 220	< LOD
H6c	2 (mask CPAP)	0	< LOD	< LOD	< LOD
H7c	2 (mask CPAP)	12	< LOD	< LOD	< LOD
H8d	2 (NIPPV)	24	49 400	18 150	< LOD
H9e	NA	NA	Not done	Not done	Not done

DEHP di-(2-ethylhexyl) phthalate, MEHHP mono-(2-ethyl-5-hydroxyhexyl) phthalate, MEOHP mono-(2-ethyl-5-oxohexyl) phthalate, MEHP mono-(2-ethylhexyl) phthalate, CPAP continuous positive airway pressure, NIPPV non-invasive positive pressure ventilation, LOD level of detection

^aUrine samples (one each) were obtained on 14 subjects including 1 dropout (D), 6 normotensive (N), and 8 hypertensive (H) subjects

^bInfants with no exposures and no detectable phthalate metabolites

^cInfants with DEHP exposures (3 respiratory and 1 combined) and no detectable phthalate metabolites

^dInfants with DEHP exposures (2 respiratory and 4 combined) who had detectable urine phthalate metabolites

^eInfants where no sampling was done